scholarly journals TXNRD1 Is an Unfavorable Prognostic Factor for Patients with Hepatocellular Carcinoma

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Binsheng Fu ◽  
Wei Meng ◽  
Xiancheng Zeng ◽  
Hui Zhao ◽  
Wei Liu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Prognostic Factor ◽  
Clinical Stage ◽  
Thioredoxin Reductase ◽  
Immunohistochemical Analysis ◽  
Independent Prognostic Factor ◽  
Clinical Samples ◽  
Kaplan Meier ◽  
Thioredoxin Reductase 1 ◽  
N Classification

Thioredoxin reductase 1 (TXNRD1) which is a selenocysteine-containing protein is overexpressed in many malignancies. Its role in the hepatocellular carcinoma (HCC) prognosis has not been investigated. In this study, we investigated whether TXNRD1 functions as an independent prognostic factor for HCC patients. We found TXNRD1 was overexpressed in HCC tissues and cells, immunohistochemical analysis suggested TXNRD1 was elevated in 57 of 120 (47.5%) clinical samples, and its level was increased with the increasing clinical stage. In addition, TXNRD1 expression was positively correlated with clinical stage (p=3.5e-5), N classification (p=4.4e-4), and M classification (p=0.037) of HCC patients. Kaplan-Meier analysis revealed that patients with high TXNRD1 expression had significantly shorter survival time than patients with low TXNRD1 expression. Multivariate analysis found TXNRD1 was an independent prognostic factor for HCC patients. In conclusion, our data suggested that TXNRD1 was a biomarker for the prognosis of patients with HCC.

scholarly journals The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Takuma Kagami ◽  
Mihoko Yamade ◽  
Takahiro Suzuki ◽  
Takahiro Uotani ◽  
Shinya Tani ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Prognostic Value ◽  
Clinical Stage ◽  
In Vitro Study ◽  
Independent Prognostic Factor ◽  
Esophageal Function ◽  
Kaplan Meier ◽  
Potential Biomarker ◽  
Highly Sensitive

Abstract Background Schlafen 11 (SLFN11) was recently identified as a dominant determinant of sensitivity to DNA-targeting agents including platinum-based drugs. SLFN11 also reportedly enhances cellular radiosensitivity. In this study, we examined the prognostic value of SLFN11 expression in esophageal squamous cell carcinoma (ESCC) patients treated with definitive chemoradiotherapy (dCRT), including the platinum derivative nedaplatin. Methods Seventy-three patients with ESCC who received dCRT were examined. SLFN11 expression was analyzed in pre-dCRT biopsies using immunohistochemistry and evaluated using a histo-score (H-score). Correlation between the H-score and overall survival was analyzed. An H-score ≥ 51 was provisionally defined as indicating high SLFN11 expression. Viability assays were performed using previously established isogenic human cell lines differentially expressing SLFN11 to test the usefulness of SLFN11 as marker of response to the dCRT regimen. Results High SLFN11 expression was independently associated with better prognosis in ESCC patients (hazard ratio = 0.295, 95% CI = 0.143–0.605, p = 0.001 for multivariate analysis). Kaplan-Meier survival curves showed that the prognostic value of high SLFN11 expression was most evident in patients at clinical stages II and III (p = 0.004). In in vitro study, SLFN11-proficient cells were highly sensitive to platinum derivatives compared to SLFN11-deficient cells. Conclusion SLFN11 expression is an independent prognostic factor for ESCC patients treated with dCRT and a potential biomarker for treatment selection of ESCC. Examination of SLFN11 may be particularly useful for clinical Stage II–III patients who wish to choose dCRT (instead of surgery) to preserve esophageal function.

scholarly journals The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy

2020 ◽  
Author(s):  
Takuma Kagami ◽  
Mihoko Yamade ◽  
Takahiro Suzuki ◽  
Takahiro Uotani ◽  
Shinya Tani ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Prognostic Value ◽  
Clinical Stage ◽  
In Vitro Study ◽  
Independent Prognostic Factor ◽  
Esophageal Function ◽  
Kaplan Meier ◽  
Potential Biomarker ◽  
Highly Sensitive

Abstract Background: Schlafen 11 (SLFN11) was recently identified as a dominant determinant of sensitivity to DNA-targeting agents including platinum-based drugs. SLFN11 also reportedly enhances cellular radiosensitivity. In this study, we examined the prognostic value of SLFN11 expression in esophageal squamous cell carcinoma (ESCC) patients treated with definitive chemoradiotherapy (dCRT), including the platinum derivative nedaplatin. Methods: Seventy-three patients with ESCC who received dCRT were examined. SLFN11 expression was analyzed in pre-dCRT biopsies using immunohistochemistry and evaluated using a histo-score (H-score). Correlation between the H-score and overall survival was analyzed. An H-score ≥ 51 was provisionally defined as indicating high SLFN11 expression. Viability assays were performed using previously established isogenic human cell lines differentially expressing SLFN11 to test the usefulness of SLFN11 as marker of response to the dCRT regimen. Results: High SLFN11 expression was independently associated with better prognosis in ESCC patients (hazard ratio = 0.295, 95% CI = 0.143–0.605, p = 0.001 for multivariate analysis). Kaplan-Meier survival curves showed that the prognostic value of high SLFN11 expression was most evident in patients at clinical stages II and III (p = 0.004). In in vitro study, SLFN11-proficient cells were highly sensitive to platinum derivatives compared to SLFN11-deficient cells. Conclusion: SLFN11 expression is an independent prognostic factor for ESCC patients treated with dCRT and a potential biomarker for treatment selection of ESCC. Examination of SLFN11 may be particularly useful for clinical Stage II–III patients who wish to choose dCRT (instead of surgery) to preserve esophageal function.

scholarly journals The First Evidence for SLFN11 Expression As An Independent Prognostic Factor for Patients with Esophageal Cancer After Chemoradiotherapy

2020 ◽  
Author(s):  
Takuma Kagami ◽  
Mihoko Yamade ◽  
Takahiro Suzuki ◽  
Takahiro Uotani ◽  
Shinya Tani ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Prognostic Value ◽  
Clinical Stage ◽  
Independent Prognostic Factor ◽  
Esophageal Function ◽  
Dna Targeting ◽  
Kaplan Meier ◽  
Potential Biomarker ◽  
Schlafen 11 ◽  
Selection Of

Abstract Background:Schlafen 11 (SLFN11) was recently identified as a dominant determinant of sensitivity to DNA-targeting agents including platinum-based drugs. SLFN11 also reportedly enhances cellular radiosensitivity. In this study, we examined the prognostic value of SLFN11 expression in esophageal squamous cell carcinoma (ESCC) patients treated with definitive chemoradiotherapy (dCRT), including the platinum derivative nedaplatin.Methods:Seventy-three patients with ESCC who received dCRT were examined. SLFN11 expression was analyzed using immunohistochemistry and evaluated using a histo-score (H-score). Correlation between the H-score and overall survival was analyzed. An H-score ≥ 51 was provisionally defined as indicating high SLFN11 expression.Results:High SLFN11 expression was independently associated with better prognosis in ESCC patients (hazard ratio = 0.295, 95% CI = 0.143–0.605, p = 0.001 for multivariate analysis). Kaplan-Meier survival curves showed that the prognostic value of high SLFN11 expression was most evident in patients at clinical stages II and III (p = 0.004).Conclusion:SLFN11 expression is an independent prognostic factor for ESCC patients treated with dCRT and a potential biomarker for treatment selection of ESCC. Examination of SLFN11 may be particularly useful for clinical Stage II–III patients who wish to choose dCRT (instead of surgery) to preserve esophageal function.

scholarly journals Onodera’s prognostic nutritional index is a strong prognostic indicator for patients with hepatocellular carcinoma after initial hepatectomy, especially patients with preserved liver function

BMC Surgery ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Akihiro Tanemura ◽  
Shugo Mizuno ◽  
Aoi Hayasaki ◽  
Kazuyuki Gyoten ◽  
Takehiro Fujii ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Prognostic Factors ◽  
Prognostic Factor ◽  
Liver Function ◽  
Prognostic Nutritional Index ◽  
Independent Prognostic Factor ◽  
Related Factors ◽  
Impaired Liver Function ◽  
Nutritional Index ◽  
Initial Hepatectomy

Abstract Background Several inflammation-based scores are used to assess the surgical outcomes of hepatocellular carcinoma (HCC). The aim of the present study was to elucidate the prognostic value of the prognostic nutritional index (PNI) in HCC patients who underwent hepatectomy with special attention to preoperative liver functional reserve. Methods Preoperative demographic and tumor-related factors were analyzed in 189 patients with HCC undergoing initial hepatectomy from August 2005 to May 2016 to identify significant prognostic factors. Results Multivariate analysis for overall survival (OS) revealed that female sex (p = 0.005), tumor size (p < 0.001) and PNI (p = 0.001) were independent prognostic factors. Compared to the High PNI group (PNI ≥ 37, n = 172), the Low PNI group (PNI < 37, n = 17) had impaired liver function and significantly poorer OS (13% vs. 67% in 5-year OS, p = 0.001) and recurrence-free survival (RFS) (8 vs. 25 months in median PFS time, p = 0.002). In the subgroup of patients with a preserved liver function of LHL15 ≥ 0.9, PNI was also independent prognostic factor, and OS (21% vs. 70% in 5-year OS, p = 0.008) and RFS (8 vs. 28 months in median PFS time, p = 0.018) were significantly poorer in the Low PNI group than the High PNI group. Conclusions PNI was an independent prognostic factor for HCC patients who underwent hepatectomy. Patients with PNI lower than 37 were at high risk for early recurrence and poor patient survival, especially in the patients with preserved liver function of LHL ≥ 0.9.

scholarly journals The prognostic value of platelet-to-lymphocyte ratio on the long-term renal survival in patients with IgA nephropathy

2020 ◽  
Author(s):  
Dan Chang ◽  
Yichun Cheng ◽  
Ran Luo ◽  
Chunxiu Zhang ◽  
Meiying Zuo ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Prognostic Value ◽  
Cox Regression ◽  
Independent Prognostic Factor ◽  
Renal Survival ◽  
Platelet To Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Female Patients ◽  
Kaplan Meier

Abstract Purpose Platelet-to-lymphocyte ratio (PLR) was established showing the poor prognosis in several diseases, such as malignancies and cardiovascular diseases. But limited study has been conducted about the prognostic value of PLR on the long-term renal survival of patients with Immunoglobulin A nephropathy (IgAN). Methods We performed an observational cohort study enrolling patients with biopsy-proven IgAN recorded from November 2011 to March 2016. The definition of composite endpoint was eGFR decrease by 50%, eGFR < 15 mL/min/1.73 m2, initiation of dialysis, or renal transplantation. Patients were categorized by the magnitude of PLR tertiles into three groups. The Kaplan–Meier curves and multivariate Cox models were performed to determine the association of PLR with the renal survival of IgAN patients. Results 330 patients with a median age of 34.0 years were followed for a median of 47.4 months, and 27 patients (8.2%) had reached the composite endpoints. There were no differences among the three groups (PLR < 106, 106 ≤ PLR ≤ 137, and PLR > 137) in demographic characteristics, mean arterial pressure (MAP), proteinuria, and estimated glomerular filtration rate (eGFR) at baseline. The Kaplan–Meier curves showed that the PLR > 137 group was significantly more likely to poor renal outcomes than the other two groups. Using univariate and multivariate cox regression analyses, we found that PLR > 137 was an independent prognostic factor for poor renal survival in patients with IgAN. Subgroup analysis revealed that the PLR remained the prognostic value for female patients or patients with eGFR less than 60 mL/min/1.73 m2. Conclusions Our results underscored that baseline PLR was an independent prognostic factor for poor renal survival in patients with IgAN, especially for female patients or those patients with baseline eGFR less than 60 mL/min/1.73 m2.

Focal adhesion kinase is overexpressed in hepatocellular carcinoma and can be served as an independent prognostic factor

2004 ◽  
Vol 41 (1) ◽  
pp. 104-111 ◽  
Author(s):  
Tsutomu Fujii ◽  
Katsumi Koshikawa ◽  
Shuji Nomoto ◽  
Osamu Okochi ◽  
Tetsuya Kaneko ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Prognostic Factor ◽  
Focal Adhesion Kinase ◽  
Focal Adhesion ◽  
Independent Prognostic Factor

Can Systemic Immune-Inflammation Index Create a New Perspective for the IMDC Scoring System in Patients with Metastatic Renal Cell Carcinoma?

2021 ◽  
pp. 1-8
Author(s):  
Fatma Bugdayci Basal ◽  
Cengiz Karacin ◽  
Irem Bilgetekin ◽  
Omur Berna Oksuzoglu
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factor ◽  
Regression Model ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Cox Regression ◽  
Independent Prognostic Factor ◽  
Cox Regression Model ◽  
Kaplan Meier

Introduction: The aim of the study was to evaluate impact of the systemic immune-inflammation index (SII) on prognosis and survival within the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score groups. Methods: The records of 187 patients with metastatic renal cell carcinoma (RCC) were reviewed retrospectively. The SII was calculated as follows: SII = Neutrophil × Platelet/Lymphocyte. The patients were categorized into 2 groups based on a median SII of 730 (×109 per 1 L) as SII low (<730) and SII high (≥730). The Kaplan-Meier method was used for survival analysis and a Cox regression model was utilized to determine independent predictors of survival. Results: The median age was 61 years (range: 34–86 years). Kaplan-Meier tests revealed significant differences in survival between the SII-low and SII-high levels (27.0 vs. 12.0 months, respectively, p < 0.001). The Cox regression model revealed that SII was an independent prognostic factor. The implementation of the log-rank test in the IMDC groups according to the SII level provided the distinction of survival in the favorable group (SII low 49.0 months vs. SII high 11.0 months, p < 0.001), in the intermediate group (SII low 26.0 vs. SII high 15.0 months, p = 0.007), and in the poor group (SII low 19.0 vs. SII high 6.0 months, p = 0.019). Conclusion: The SII was an independent prognostic factor and provided significant differences in survival for the favorable, intermediate, and poor IMDC groups. Thus, the SII added to the IMDC score may be clinically beneficial in predicting survival.

scholarly journals Bile duct invasion can be an independent prognostic factor in early stage hepatocellular carcinoma

2015 ◽  
Vol 19 (4) ◽  
pp. 167 ◽  
Author(s):  
Ye-Rang Jang ◽  
Kwang-Woong Lee ◽  
Hyeyoung Kim ◽  
Jeong-Moo Lee ◽  
Nam-Joon Yi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Bile Duct ◽  
Prognostic Factor ◽  
Early Stage ◽  
Independent Prognostic Factor ◽  
Bile Duct Invasion

scholarly journals Combining TrkA Immunohistochemical-Score with Clinicopathologic Parameters in Neuroblastoma: An Influential Prognostic Nomogram

2021 ◽  
Author(s):  
Juanqing Yue ◽  
Lei Cai ◽  
Ruifen Wang ◽  
Meng Qiao ◽  
Kezhou Wang ◽  
...  
Keyword(s):  
In Situ Hybridization ◽  
Prognostic Factor ◽  
Fluorescence In Situ Hybridization ◽  
Gene Fusion ◽  
Independent Prognostic Factor ◽  
Clinical Samples ◽  
Qrt Pcr ◽  
Clinicopathologic Parameters ◽  
Low Expression

Abstract BackgroundNeuroblastoma (NB) is one of the most common solid tumors in children with varied clinical outcomes. Although there are some several risk stratification systems currently, their clinical applications are limited due to the testing conditions of different laboratory and the heavy financial burden on patients. TrkA is coded by NTRK1 , belonging to tropomyosin receptor kinase family. We have observed that TrkA was differentially expressed in paraffin tissue sections of NB. The aim of this study was to determine the immunohistochemical-score of TrkA as an independent prognostic factor for NB and establish a useful prognostic model for postoperative patients.MethodsWe systematically summarized the relationship between immunochemistry (IHC) score of TrkA and clinicopathological parameters in 86 NB cases. Fluorescence in situ hybridization (FISH) and qRT-PCR were used to detect NTRK1 gene fusion. Furthermore, GSE96631, GSE16476, GSE49710 and GSE73537 datasets, originated from Gene Expression Omnibus (GEO), were analyzed to figure out the NTRK1 related molecular characteristics by bioinformatics methods. And combined TrkA immunohistochemical-score with clinicopathologic parameters to construct a prognostic nomogram of overall survival (OS) for NB.ResultIn clinical samples and GEO database analyses, patients in the NTRK1 / TrkA low expression group showed significantly poorer outcome than patients in high group. Multivariate cox regression analysis demonstrated NTRK1 / TrkA as an independent prognostic factor for NB survival. Neither Fluorescence in situ hybridization nor qRT-PCR detected evidence for NTRK1 gene fusion in clinical samples, indicating that differential expression in NTRK1 / TrkA are caused by epigenetic changes. Bioinformatics analyses revealed that MYC target related pathway may play a critical role in low expression of TrkA, leading to unfavorable prognoses of NB.ConclusionThe results of this study suggest that the IHC score of TrkA may be used as an independent predictor of postoperative OS of patients with NB. By combining the IHC score of TrkA and clinicopathological features, the proposed nomogram provides a feasible predictive tool for postoperative patients with NB. Simultaneously, this study also reveals that Trk inhibitors are not supposed to be taken in NB patients.

Sign in / Sign up

Export Citation Format

Share Document